In Europe, Velcade-Based Regimens are the Most Commonly Prescribed Treatments for First-Line Myeloma, While MabThera Experiences Significant Use Across All NHL Therapy Lines

BURLINGTON, Mass., June 11, 2014 /PRNewswire/ -- Decision Resources Group finds that regimens based on Janssen's Velcade are the most commonly prescribed treatments for first-line multiple myeloma (MM), according to surveyed hematological oncologists from France, Germany, Italy and Spain.... Reported by PR Newswire 3 hours ago.